Table 2.

The results of the meta-analyses of RCT assessing the efficacy of GnRHa given before/during chemotherapy.

Reference	Endpoint	No. of patients	Results GnRHa vs control	P value
Pro
Lambertini, 2015	POF	1231	18.5% vs 33.5%, OR = 0.36	<0.001
	1-year Amenorrhea	882	31% vs 42.9%, OR = 0.55	<0.001
	PR	706	33 vs 9, OR = 1.83	0.041
	DFS	626	19.5% vs 18.8%, HR = 1.00	0.939
Shen, 2015	POF	1064	OR 2.57, 95% CI 1.65–4.01	0.0001
	PR		OR 0.177; 95% CI = 0.92, 1.40	0.09
Del Mastro, 2014	POF	765	OR = 0.43; 95% CI: 0.22–0.84	0.013
Sun, 2014	POF	621	9.66% vs 26.67%, RR of 0.45, 95% CI 0.22–0.92	0.02
Yang, 2013	POF	528	RR of 0.40, 95% CI 0.21–0.75
	RM		RR = 1.31, 95% CI 0.93–1.85
	PR		RR = 0.96, 95% CI 0.20–4.56
Wang, 2013	RM	677	OR 2.681; 95% CI, 1.169–6.146
Chen, 2011	RM		RR 1.90, 95% CI 1.30–2.79
	Amenorrhea		RR 0.08, 95% CI 0.01–0.58
	Ovulation		RR 2.70, 95% CI 1.52–4.79
	PR		RR 0.21, 95% CI 0.01–4.09
Bedaiwy, 2011	RM	340	57.22% vs 35.22%	0.03
			OR 3.46; 95% CI, 1.13–10.57
	Spontaneous	98	60.41% vs 22%	0.0002
	Ovulation		OR 5.70; 95% CI, 2.29–14.20
Munhoz, 2016	RM 6 months	856	OR = 2.41; 95% CI 1.40–4.15	0.002
	RM 12 months	778	OR 1.85; 95% CI 1.33–2.59	0.0003
	PR	218	OR 1.85; 95% CI 1.02–3.36	0.04
Contra
Elgindy, 2015	RM	907	68.4% vs 59.9%, RR 1.12, 95% CI 0.99–1.27	0.7
	PR		RR 1.63, 95% CI 0.94–2.82

CI, confidence interval; DFS, disease-free survival; OR, odds ratio; POF, premature ovarian failure; PR, pregnancy rate; RCT, randomized clinical trials; RM, resumption of menses; RR, relative risk.